Climb Bio Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Climb Bio.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Climb Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | N/A | -64 | 0 | 0 | N/A |
| 3/31/2024 | N/A | -15 | -7 | -7 | N/A |
| 12/31/2023 | N/A | -35 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -39 | -28 | -28 | N/A |
| 6/30/2023 | N/A | -45 | -36 | -36 | N/A |
| 3/31/2023 | N/A | -54 | -42 | -42 | N/A |
| 12/31/2022 | N/A | -45 | -37 | -37 | N/A |
| 9/30/2022 | N/A | -48 | -37 | -37 | N/A |
| 6/30/2022 | N/A | -49 | -46 | -46 | N/A |
| 3/31/2022 | N/A | -46 | -40 | -40 | N/A |
| 12/31/2021 | N/A | -52 | -36 | -36 | N/A |
| 9/30/2021 | N/A | -57 | -34 | -34 | N/A |
| 6/30/2021 | N/A | -49 | -23 | -23 | N/A |
| 3/31/2021 | N/A | -40 | -19 | -19 | N/A |
| 12/31/2020 | N/A | -23 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CLYM's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if CLYM's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CLYM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CLYM's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CLYM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLYM's Return on Equity is forecast to be high in 3 years time